Figure 2From: Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathologyEffects of LY window therapy on amyloid deposition. A. Quantitative burden analysis of cored amyloid deposits and CAA in the 4-7M LY treated group compared to controls. (*p < 0.05, Student’s t test). B. Representative brain sections stained with mAb 13.1.1 showing cored plaque and CAA immune-reactivity at 15M in the brains of Control and 4-7M LY treated Tg2576 mice. Arrows indicate CAA in meningeal vessels. Scale bar = 80 μm. C. Biochemical analyses of FA solubilized Aβ levels and plaque burden analysis from Tg2576 mice transiently dosed with LY (2.5mpk/day) from 4-7M, and aged to 18M. (*p < 0.05, Student’s t test). Tg2576 mice (n = 5-6/group) were used, data represented is from one independent experiment. D. Natural logarithm transformed Aβ values of untreated Tg2576 mice (at indicated ages) and Aβ levels from 4-7M LY treatment measured at 15M and 18M of age. E. Biochemical analyses of FA solubilized Aβ levels of Tg2576 mice transiently dosed with LY (2.5mpk/day) at 1, 2, and 3M intervals and then aged till 15M. (*p < 0.05, ANOVA). Tg2576 mice (n = 5-8/group) were used, data represented is from one independent experiment. F. Graph representing Aβ values of untreated Tg2576 mice (from indicated ages) and Aβ levels from 4-5M, 4-6M and 4-7M LY transient treatment measured at 15M. FA solubilized brain Aβ42 + Aβ40 levels measured by ELISA are shown.Back to article page